AstraZeneca Pharma India surges on launching Fasenra in India
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Astrazeneca Pharma India is currently trading at Rs. 3905.70, up by 314.95 points or 8.77% from its previous closing of Rs. 3590.75 on the BSE.
The scrip opened at Rs. 3735.00 and has touched a high and low of Rs. 3971.00 and Rs. 3713.50 respectively. So far 34234 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 4970.00 on 08-Sep-2020 and a 52 week low of Rs. 2540.00 on 22-Apr-2020.
Last one week high and low of the scrip stood at Rs. 3971.00 and Rs. 3410.00 respectively. The current market cap of the company is Rs. 9764.25 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 3.82% and 21.18% respectively.
AstraZeneca Pharma India has launched Fasenra in India. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.
Earlier, the company had received Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra).
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
